Monitor for patent office actions and any subsequent licensing or partnership announcements. The patent expansion is a positive IP step but does not change near-term fundamentals. Recent dilutive offering (April 2026) still overhangs the stock.
Price Chart
Executive Summary
Polyrizon announced submission of amended claims in a U.S. patent application for its intranasal drug delivery platform, expanding IP protection to include drug delivery systems and methods of use. The press release is forward-looking and does not guarantee patent issuance or revenue. The filing is routine IP news with no material financial impact.
Key Facts
- Filed amended claims with U.S. Patent Office for intranasal drug delivery platform
- Expanded claims cover mucoadhesive compositions, drug delivery systems, and methods of use
- Platform aims to improve drug residence time, bioavailability, and film formation on mucosal tissues
- Company is a development-stage biotech with no current revenue; relies on future patent protection and commercialization
- No financial data or guidance provided in the filing
Financial Impact
No direct financial impact; patent expansion is an intangible asset development
Risk Factors
- Patent may not be granted; scope of allowed claims uncertain
- No revenue or near-term commercialization expected
- Recent capital raise dilutes existing shareholders
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-051171 |
| Document: ea0288888-6k_polyrizon.htm | 0001213900-26-051171 |
| Document: 0001213900-26-051171-index-headers.html | 0001213900-26-051171 |
| Document: 0001213900-26-051171-index.html | 0001213900-26-051171 |
| Document: 0001213900-26-051171.txt | 0001213900-26-051171 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | 6-K | $9.01 | awaiting T+1 | — | $8.58 (−4.77%) |
Oct 27, 2026 today | Press Release | $9.01 | awaiting T+1 | — | $8.58 (−4.77%) |
Oct 5, 2026 22d ago | 6-K | $9.67 $9.15 | ▼ −5.37% | ▼ −5.13% | $8.58 (−11.27%) |
Oct 2, 2026 25d ago | EFFECT | $9.61 $9.26 | ▲ +3.64% | ▲ +4.32% | $8.58 (+10.72%) |
Sep 22, 2026 5w ago | Press Release | $10.66 $11.16 | ▲ +4.69% | ▲ +5.41% | $8.58 (−19.51%) |
Sep 18, 2026 5w ago | F-1 | $10.90 $10.66 | ▲ +2.20% | ▲ +2.19% | $8.58 (+21.28%) |
Sep 4, 2026 7w ago | Press Release | $11.24 $11.15 | ▲ +0.80% | ▲ +0.25% | $8.58 (+23.67%) |
Sep 4, 2026 7w ago | 6-K | $11.24 $11.15 | ▲ +0.80% | ▲ +0.25% | $8.58 (+23.67%) |
Sep 4, 2026 7w ago | 424B5 | $11.24 $11.15 | ▲ +0.80% | ▲ +0.25% | $8.58 (+23.67%) |
Aug 20, 2026 9w ago | 6-K | $10.30 $10.70 | ▲ +3.88% | ▲ +4.18% | $8.58 (−16.70%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers